A comparison between low doses of amitriptyline and low doses of fluoxetin used in the control of depression in patients suffering from Parkinson's disease;Dosis bajas de amitriptilina frente a dosis bajas de fluoxetina en el tratamiento de la depresión de enfermos con Parkinson

Revista de Neurologia

Volumn 35, Issue 11, 2002, Pages 1010-1014

  Serrano Dueñas, Marcos ^a,b  

^a HOSPITAL CARLOS ANDRADE MARÍN   (Ecuador)

^b NONE   (Ecuador)

Author keywords

Amitriptyline; Depression; Fluoxetin; Parkinson

Indexed keywords

AMITRIPTYLINE; FLUOXETINE;

ADULT; AGED; ARTICLE; CAUDATE NUCLEUS; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; LATERAL GENICULATE BODY; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; PARKINSON DISEASE; PSYCHIATRIC DIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036972222     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3511.2001044     Document Type: Article

References (33)

1. Poewe W, Luginger E. Depression in Parkinson's disease. Impediment to recognition and treatment options. Neurology 1999; 52 (Suppl 3): S2-6.
2. Bieliauskas LA, Klawans HL, Glantz RH. Depression and cognitive changes in Parkinson's disease: a review. In Yahr MD, Bergmann KJ, eds. Parkinson's Disease. Advances in Neurology. Vol. 45. New York: Raven Press; 1986. p. 437-8.
3. Bum DJ. Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease. Mov Disord 2002; 17: 445-54.
4. Starkstein SE, Petracca G, Chemerinski E, Tesón A, Sabe L, Merello M, et al. Depression in classical versus akinetic-rigid Parkinson's disease. Mov Disord 1988; 3: 29-33.
5. Hammond-Tooke G, Pollock M. Depression, dementia, and Parkinson's disease. In Joseph AB, Young RR, eds. Movement disorders in neurology and neuropsychiatry. 2 ed. Massachusetts: Blackwell Science; 1999. p. 195-204.
6. Levy ML, Cummings JL. Parkinson's disease and parkinsonism. In Joseph AB, Young RR, eds. Movement disorders in neurology and neuropsychiatry. 2 ed. Massachusetts: Blackwell Science; 1999. p. 171-9.
7. Foti DJ, Cummings JL. Neurobehavioral aspects of movement disorders. In Watts RL, Koller WC, eds. Movement disorders. Neurologic principles and practice. New York: McGraw-Hill; 1997. p. 15-30.
8. Tekin S, Cummings JL. Frontal-subcortical neuronal circuits and clinical neuropsychiatry. An update. J Psychosom Res 2002; 53: 647-54.
9. Estévez-González A, García-Sánchez C, Barraquer-Bordas L. Los lóbulos frontales: el cerebro ejecutivo. Rev Neurol 2000; 31: 566-77.
10. Melamed E. Neurobehavioral abnormalities in Parkinson's disease. In Watts RL, Koller WC, eds. Movement disorders. Neurologic principles and practice. New York: McGraw-Hill; 1997. p. 257-62.
11. Kaplan HI, Sadock BJ, Grebb JA. Sinopsis de psiquiatría. 7 ed. Buenos Aires: Médica Panamericana; 1996.
12. Baldessarini RJ. Drugs and the treatment of psychiatric disorders. Depression and mania. In Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman-Gilman A, eds. Goodman & Gilman's The Pharmacological basis of therapeutics. 9 ed. New York: McGraw-Hill; 1996. p. 431-59.
13. Jachna JS, Lane RD, Gelenberg AJ. Psychopharmacology. In Rundell JR, Wise MG, eds. Textbook of consultation-liaison psychiatry. Washington: American Psychiatric Press; 1996. p. 958-1005.
14. Olanow CW, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. Neurology 1998; 50 (Suppl 3): S 1-57.
15. Calne DB, Snow DB, Lee C. Criteria for diagnosis in Parkinson's disease. Ann Neurol 1992; 32: 125-7.
16. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
17. Kokmen E, Naessens JM, Offord KP. A short test of mental status: description and preliminary results. Mayo Clin Proc 1987; 62: 281-8.
18. Fahn S, Elton RL, Members of The UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent development in Parkinson's disease. Vol. 2. New Jersey: McMillan; 1987. p. 153-63.
19. Dawson-Saunders B, Trapp RG. Bioestadística médica. México DF: El Manual Moderno; 1993.
20. Rouchell AM, Pounds R, Tierney JG. Depression. In Rundell JR, Wise MG, eds. Textbook of consultation-liaison psychiatry. Washington: American Psychiatric Press; 1996. p. 310-45.
21. Levin BE, Tomer R, Rey GJ. Cognitive impairment in Parkinson's Disease. Neurol Clin 1992; 10: 471-85.
22. Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG. Depression in Parkinson's disease. J Nerv Ment Dis 1990; 178: 27-31.
23. Mayeux R. Depression in the patient with Parkinson's disease. J Clin Psychiatry 1990; 52: 20-3.
24. Doris A, Ebmeier K, Shajahan P. Depressive illness. Lancet 1999; 354: 1369-75.
25. Huber SJ, Shuttleworth EC, Paulson GW. Dementia in Parkinson's disease. Arch Neurol 1986; 43: 987-90.
26. Richard IH, Maughn A, Kurlan R. Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series. Mov Disord 1999; 14: 155-7.
27. Caley CF, Friedman JH. Does fluoxetine exacerbate Parkinson's disease. J Clin Psychiatry 1992; 53: 278-82.
28. Task Force Commissioned by The Movement Disorders Society. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002; 17 (Suppl 4): S112-9.
29. Montgomery SA. The place of reboxetine in antidepressant therapy. J Clin Psychiatry 1998; 59 (Suppl 14): S26-9.
30. Bech P, Cialdella P, Haugh MC, Birkett MA, Hours A, Boissel JP, et al. Meta-analysis of randomised controlled trials of fluoxetine vs placebo and tricyclic antidepressants in the short-term treatment of major depression. Br J Psychiatry 2000; 176: 421-8.
31. Freemantle N, Anderson IM, Young P. Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Meta-regression analysis. Br J Psychiatry 2000; 177: 292-302.
32. Kirby M, Denihan A, Brice I, Radic A, Coakley D, Lawlor BA. Influence of symptoms of anxiety on treatment of depression in later life in primary care: questionnaire survey. Br Med J 1999; 318: 579-80.
33. Schrag A, Jahanshhahi M, Quinn, N. How does Parkinson's disease affect quality of life? A comparison with quality of life in general population. Mov Disord 2000; 15: 1112-8.